Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation

被引:13
|
作者
Varughese, George I. [1 ]
Patel, Jeetesh V. [1 ]
Tomson, Joseph [1 ]
Lip, Gregory Y. H. [1 ]
机构
[1] Univ Birmingham, Haemostasis Thrombosis & Vasc Biol Unit, Dept Med, City Hosp, Birmingham, W Midlands, England
关键词
D O I
10.1136/hrt.2006.099374
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased levels of plasma von Willebrand factor (vWf, an index of endothelial damage/dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations have been reported as indices of the prothrombotic state in both non-valvular atrial fibrillation and hypertension separately. However, the effect of hypertension on the levels of these indices in the setting of atrial fibrillation, and whether increasing severity of hypertension presents an additive prothrombotic risk, is unclear. Methods: Plasma concentrations of vWf and sP-sel were measured by ELISA in 1235 patients with atrial fibrillation, and levels related to a history of hypertension and rising quartiles of systolic, diastolic and pulse pressure in those with and without diabetes mellitus and prior vascular events. Results: Mean plasma vWf was higher among patients with atrial fibrillation with a history of hypertension (149 vs 145 IU/dl, p = 0.005). Also, an increase in the levels of vWf with increasing quartiles of pulse pressure (p = 0.042) was noticed. However, on multivariate analysis, after adjusting for potential confounders, the effects of both hypertension and pulse pressure became non-significant (p = 0.261 and p = 0.5, respectively). Levels of sP-sel were unaffected by a history of hypertension and rising quartiles of systolic and diastolic blood pressure, or pulse pressure. Conclusion: Among patients with atrial fibrillation, patients with hypertension have higher vWf levels, indicating endothelial damage/dysfunction, which is associated with increasing pulse pressure. However, these associations are probably owing to the presence of other associated cardiovascular disease, rather than hypertension itself. Furthermore, platelet activation (sP-sel) was unrelated to hypertension or blood pressure in this atrial fibrillation cohort. Hypertension or blood pressure levels do not seem to have an independent additive affect on the prothrombotic state in atrial fibrillation.
引用
收藏
页码:495 / 499
页数:5
相关论文
共 50 条
  • [41] ABO blood groups: A risk factor for left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation
    Fu, Yuan
    Li, Kuibao
    Yang, Xinchun
    THROMBOSIS RESEARCH, 2017, 156 : 45 - 50
  • [42] Association between oral anticoagulants and risk of dementia in patients with non-valvular atrial fibrillation
    Rahman, Alvi
    Michaud, Jonathan
    Dell'Aniello, Sophie
    Moodie, Erica
    Brophy, James M.
    Durand, Madeleine
    Guertin, Jason
    Boivin, Jean-Francois
    Renoux, Christel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 631 - 631
  • [43] Ischemic Stroke and Bleeding Risk in Patients with Non-valvular Atrial Fibrillation Treated with Warfarin
    He, S. B.
    Yu, S. H.
    Meng, R.
    Ru, S. W.
    Gong, Z. J.
    Liu, H. M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S406 - S406
  • [44] INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
    Chung, Jee Eun
    Choi, Yoo Ri
    Seong, Jong Mi
    La, Hyen O.
    Gwak, Hye Sun
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (06) : 1038 - 1046
  • [45] Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation have a Risk for Aortogenic Embolizations
    Kojima, Keisuke
    Fukamachi, Daisuke
    Okumura, Yasuo
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (07) : 786 - 788
  • [46] Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
    Dzeshka, Mikhail S.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2661 - 2678
  • [47] INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
    Jee Eun Chung
    Yoo Ri Choi
    Jong Mi Seong
    Hyen O La
    Hye Sun Gwak
    International Journal of Clinical Pharmacy, 2015, 37 : 1038 - 1046
  • [48] Risk of ischemic stroke associated with DOAC discontinuation on patients with non-valvular atrial fibrillation
    Tlvaro Thomsen, Tobias
    Mesa Guadalupe, Jorge
    Cea Soriano, Lucia
    Huerta, Consuelo
    De Burgos, Airam
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 75 - 75
  • [49] Risk of ischemic stroke and hemorrhagic complications in warfarinized patients with non-valvular atrial fibrillation
    Uchiyama, S
    INTERNAL MEDICINE, 2001, 40 (12) : 1166 - 1167
  • [50] Novel Anticoagulants for Non-valvular Atrial Fibrillation
    Xu, Bo
    Whitbourn, Robert
    HEART LUNG AND CIRCULATION, 2012, 21 (08): : 463 - 467